Genistein inhibits aldose reductase activity and high glucose-induced TGF-β2 expression in human lens epithelial cells

European Journal of Pharmacology

Volumn 594, Issue 1-3, 2008, Pages 18-25

  Kim, Young Sook ^a   Kim, Nan Hee ^a   Jung, Dong Ho ^a   Jang, Dae Sik ^a   Lee, Yun Mi ^a   Kim, Jong Min ^a   Kim, Jin Sook ^a  

^a Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

Aldose reductase; Diabetic complications; Genistein; Human lens epithelial (HLE B3) cells; Transforming growth factor 2

Indexed keywords

ALDEHYDE REDUCTASE; ALPHAB CRYSTALLIN; CRYSTALLIN; FIBRONECTIN; GENISTEIN; GLUCOSE; GLUTATHIONE; MESSENGER RNA; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CATARACT; CELL CULTURE; CELL LINE; CONTROLLED STUDY; CULTURE MEDIUM; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; DRUG PURIFICATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIUM CELL; HUMAN; HUMAN CELL; LENS EPITHELIUM; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATION; PLANT ROOT; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; PUERARIA; PUERARIA LOBATA; RAT; SPRAGUE DAWLEY RAT;

ALDEHYDE REDUCTASE; CELL LINE; CELL SURVIVAL; CORNEAL OPACITY; CRYSTALLINS; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; FIBRONECTINS; GENISTEIN; GLUCOSE; HUMANS; LENS, CRYSTALLINE; PROTECTIVE AGENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA2; XYLOSE;

EID: 50549095066     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.07.033     Document Type: Article

References (49)

1. Ae Park S., Choi M.S., Cho S.Y., Seo J.S., Jung U.J., and Kim M.J. Genistein and daidzein modulate hepatic glucose and lipid regulating enzyme activities in C57BL/KsJ-db/db mice. Life Sci. 79 (2006) 1207-1213
2. Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res. Clin. Pract. 67 (2005) 3-21
3. Akamine E.H., Hohman T.C., Nigro D., Carvalho M.H., de Cássia Tostes R., and Fortes Z.B. Minalrestat, an aldose reductase inhibitor, corrects the impaired microvascular reactivity in diabetes. J. Pharmacol. Exp. Ther. 304 (2003) 1236-1242
4. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., and Itoh N. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262 (1987) 5592-5595
5. Altomare E., Grattagliano I., Vendemaile G., Micelli-Ferrari T., Signorile A., and Cardia L. Oxidative protein damage in human diabetic eye: evidence of a retinal participation. Eur. J. Clin. Invest. 27 (1997) 141-147
6. Asnaghi V., Gerhardinger C., Hoehn T., Adeboje A., and Lorenzi M. A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes 52 (2003) 506-511
7. Brownlee M. The Pathobiology of diabetic complications: a unifying mechanism. Diabetes 54 (2005) 1615-1625
8. Chung Y.-S., Choi Y.-H., Lee S.-J., Choi S., Lee J.-H., Kim H., and Hong E.-K. Water extract of Aralia elata prevents cataractogenesis in vitro and in vivo. J. Ethnopharmacol. 101 (2005) 49-54
9. de Iongh R.U., Wederell E., Lovicu F.J., and McAvoy J.W. Transforming growth factor-beta-induced epithelial-mesenchymal transition in the lens: a model for cataract formation. Cells Tissues Organs 179 (2005) 43-55
10. Dufrane S.P., Malaisse W.J., and Sener A. A micromethod for the assay of aldose reductase, its application to pancreatic islets. Biochem. Med. 32 (1984) 99-105
11. Figarola J.L., Scott S., Loera S., Tessler C., Chu P., and Weiss L. LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats. Diabetologia 46 (2003) 1140-1152
12. Hirakata M., Kaname S., Chung U.G., Joki N., Hori Y., Noda M., Takuwa Y., Okazaki T., Fujita T., Katoh T., and Kurokawa K. Tyrosine kinase dependent expression of TGF-beta induced by stretch in mesangial cells. Kidney Int. 51 (1997) 1028-1036
13. Hosler M.R., Wang-Su S.T., and Wagner B.J. Role of the proteasome in TGF-beta signaling in lens epithelial cells. Invest. Ophthalmol. Vis. Sci. 47 (2006) 2045-2052
14. Huang R., Shi F., Lei T., Song Y., Hughes C.L., and Liu G. Effect of the isoflavone genistein against galactose-induced cataracts in rats. Exp. Biol. Med. 232 (2007) 118-125
15. Jang D.S., Kim J.M., Lee Y.M., Kim Y.S., Kim H., and Kim J.S. Puerariafuran, a new inhibitor of advanced glycation end products (AGEs) isolated from the roots of Pueraria lobata. Chem. Pharm. Bull. 54 (2006) 1315-1317
16. Jain S.K., McVie R., and Bocchini Jr. J.A. Hyperketonemia (ketosis), oxidative stress and type 1 diabetes. Pathophysiology 13 (2006) 163-170
17. Jernigan H.M., Zigler J.S., Liu Y., Blum P.S., Merola L.O., and Stimbert C.D. Effects of xylose on monkey lenses in organ culture: a model for study of sugar cataracts in a primate. Exp. Eye Res. 67 (1998) 61-71
18. Kampmeier J., Baldysiak-Figiel A., and de Jong-Hesse Y. Effect of growth factors on proliferation and expression of growth factor receptors in a human lens epithelial cell line. J. Cataract Refract. Surg. 32 (2006) 510-514
19. Kubo E., Singh D.P., and Akagi Y. Gene expression profiling of diabetic and galactosaemic cataractous rat lens by microarray analysis. Diabetologia 48 (2005) 790-798
20. Kumar P.A., Haseeb A., Suryanarayana P., Ehtesham N.Z., and Reddy G.B. Elevated expression of alphaA- and alphaB-crystallins in streptozotocin-induced diabetic rat. Arch. Biochem. Biophys. 444 (2005) 77-83
21. Kim H.Y., and Oh J.H. Screening of Korean forest plant for rat lens aldose reductase inhibition. Biosci. Biotechnol. Biochem. 63 (1999) 184-188
22. Kim W., Khil L.Y., and Clark R. Naphthalenemethyl ester derivative of dihydroxyhydrocinnamic acid, a component of cinnamon, increases glucose disposal by enhancing translocation of glucose transporter 4. Diabetologia 49 (2006) 2437-2448
23. Kim Y.S., Kim N.H., Lee S.W., Lee Y.M., Jang D.S., and Kim J.S. Effect of protocatechualdehyde on receptor for advanced glycation end products and TGF-β1 expression in human lens epithelial cells cultured under diabetic conditions and on lens opacity in streptozotocin-diabetic rats. Eur. J. Pharmacol. 569 (2007) 171-179
24. Kim Y.S., Jung D.H., Kim N.H., Lee Y.M., and Kim J.S. Effect of magnolol on TGF-β1 and fibronectin expression in human retinal pigment epithelial cells under diabetic conditions. Eur. J. Pharmacol. 562 (2007) 12-19
25. King G.L., and Loeken M.R. Hyperglycemia-induced oxidative stress in diabetic complications. Histochem. Cell Biol. 122 (2004) 333-338
26. Lee E.H., and Joo C.K. Role of transforming growth factor-beta in transdifferentiation and fibrosis of lens epithelial cells. Invest. Ophthalmol. Vis. Sci. 40 (1999) 2025-2032
27. Lee H.S., Kim B.C., Kim Y.S., Choi K.H., and Chung H.K. Involvement of oxidation in LDL-induced collagen gene regulation in mesangial cells. Kidney Int. 50 (1996) 1582-1590
28. Lee J.S. Effects of soy protein and genistein on blood glucose, antioxidant enzyme activities, and lipid profile in streptozotocin-induced diabetic rats. Life Sci. 79 (2006) 1578-1584
29. 2 and N-acetyl-l-cysteine regulate expression of c-jun and c-fos in lens systems. Exp. Eye Res. 59 (1994) 179-190
30. Liu J., Hales A.M., and Chamberlain C.G. Induction of cataract-like changes in rat lens epithelial explants by transforming growth factor beta. Invest. Ophthalmol. Vis. Sci. 35 (1994) 388-401
31. Marles R.J., and Farnsworth N.R. Antidiabetic plants and their active constituents. Phytomedicine 2 (1995) 137-189
32. Naderi G.A., Asgary S., and Sarraf-Zadegan N. Anti-oxidant effect of flavonoids on the susceptibility of LDL oxidation. Mol. Cell. Biochem. 246 (2003) 193-196
33. Ochiai Y., and Ochiai H. Higher concentration of transforming growth factor-beta in aqueous humor of glaucomatous eyes and diabetic eyes. Jpn. J. Ophthalmol. 46 (2002) 249-253
34. Padival S., and Nagaraj R.H. Pyridoxamine inhibits maillard reactions in diabetic rat lenses. Ophthalmic Res. 38 (2006) 294-302
35. Paul J.T. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch. Biochem. Biophys. 419 (2003) 31-40
36. Preet A., Siddiqui M.R., Taha A., Badhai J., Hussain M.E., Yadava P.K., and Baquer N.Z. Long-term effect of Trigonella foenum graecum and its combination with sodium orthovanadate in preventing histopathological and biochemical bnormalities in diabetic rat ocular tissues. Mol. Cell. Biochem. 289 (2006) 137-147
37. Saika S. TGF-beta pathobiology in the eye. Lab. Invest. 86 (2006) 106-115
38. Sharma S., Kulkarni S.K., and Chopra K. Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clin. Exp. Pharmacol. Physiol. 33 (2006) 940-945
39. Shuba L.M., Asai T., Pelzer S., and McDonald T.F. Activation of cardiac chloride conductance by the tyrosine kinase inhibitor, genistein. Br. J. Pharmacol. 119 (1996) 335-345
40. Sohn E.J., Kim C.S., Kim Y.S., Jung D.H., Jang D.S., Lee Y.M., and Kim J.S. Effects of magnolol (5,5'-diallyl-2,2'-dihydroxybiphenyl) on diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats. Life Sci. 80 (2007) 468-475
41. Stirban A., Negrean M., Stratmann B., Gawlowski T., Horstmann T., and Götting C. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 29 (2006) 2064-2071
42. Sun W., Gerhardinger C., Dagher Z., Hoehn T., and Lorenzi M. Aspirin at low-intermediate concentrations protects retinal vessels in experimental diabetic retinopathy through non-platelet-mediated effects. Diabetes 54 (2005) 3418-3426
43. Sun W., Oates P.J., Coutcher J.B., Gerhardinger C., and Lorenzi M. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes 55 (2006) 2757-2762
44. Takemoto L., and Boyle D. The possible role of a-crystallins in human senile cataractogenesis. Int. J. Biol. Macromol. 22 (1998) 331-337
45. Tanimoto M., Gohda T., Kaneko S., Hagiwara S., Murakoshi M., and Aoki T. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metabolism 56 (2007) 160-167
46. Van Heyningen R. Formation of polyol by the lens of the rat with sugar cataract. Nature 184 (1959) 194-196
47. Wang H.X., and Ng T.B. Natural products with hypoglycemic, hypotensive, hypocholesterolemic, antiatherosclerotic and antithrombotic activities. Life Sci. 65 (1999) 2663-2677
48. Wenzhuo D., Haimin G., Jiafu W., Yi D., Tongmei L., Jianying W., and Li Y. Preventing and treating actions of compound lian zhu capsule on micrangium lesions in diabetic rats. J. Tradit. Chin. Med. 25 (2005) 148-152
49. Ziegler D., Reljanovic M., and Mehnert H. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp. Clin. Endocrinol. Diabetes 107 (1999) 421-430